Burkitt Lymphoma Translocation
Burkitt Lymphoma Translocation At Acibadem Healthcare Group, our team of specialists and researchers continuously strive to enhance our understanding of the underlying genetic mechanisms driving Burkitt lymphoma. Through meticulous cancer research, we aim to further improve diagnostic accuracy and develop targeted treatment strategies to improve patient outcomes.
Burkitt lymphoma is a fast-growing cancer that predominantly affects the lymphatic system. It is categorized as a non-Hodgkin lymphoma and is known for its rapid progression if left untreated. Our in-depth investigation into the role of translocation in cancer genetics provides valuable insights into the development and management of this challenging disease.
We will delve into the specific translocations associated with Burkitt lymphoma, such as MYC, BCL2, and BCL6, which play crucial roles in the pathogenesis of this malignancy. Understanding the impact of these genetic alterations on abnormal gene expression and cell growth is key to shaping effective treatment strategies.
Get Free Consultation
ACIBADEM Health Point: The Future of Healthcare
We believe that everyone deserves access to quality healthcare, which is why we have established multiple branches in strategic locations. Whether you're in need of routine check-ups, specialized treatments, or emergency care, ACIBADEM Health Point is here for you.Furthermore, this article will explore the significance of translocations as diagnostic markers in Burkitt lymphoma. Identifying these translocations aids in accurate disease classification, enabling oncologists to deliver targeted therapies for improved patient care.
Stay tuned as we also discuss the cutting-edge treatment modalities available for Burkitt lymphoma, including targeted therapy, chemotherapy, and immunotherapy. These therapies offer renewed hope and better survival rates for patients battling this aggressive form of cancer.
Through continuous scientific advancements and research, Acibadem Healthcare Group remains at the forefront of oncology, providing innovative treatment options and compassionate care to patients with diverse needs.
ACIBADEM Health Point: Your Health is Our Priority!
ACIBADEM Health Point, we are dedicated to providing exceptional healthcare services to our patients. With a team of highly skilled medical professionals and state-of-the-art facilities, we strive to deliver the highest standard of care to improve the health and well-being of our patients. What sets ACIBADEM Health Point apart is our patient-centered approach. We prioritize your comfort, safety, and satisfaction throughout your healthcare journey. Our compassionate staff ensures that you receive personalized care tailored to your unique needs, making your experience with us as seamless and comfortable as possible.In the following sections, we will highlight the latest breakthroughs in cancer research, ongoing studies, and future directions for improving Burkitt lymphoma outcomes. Join us as we explore the fascinating world of cancer genetics and pave the way for a brighter future in oncology care.
Understanding Burkitt Lymphoma
Burkitt lymphoma is a type of cancer that falls under the category of non-Hodgkin lymphoma. It is characterized by its fast-growing nature and is known for its aggressive behavior. This form of lymphoma is rare but can occur in both children and adults.
Burkitt lymphoma was first identified in the 1950s by the surgeon Denis Burkitt, while he was working in Uganda. This discovery led to significant advancements in the field of oncology and cancer research.
The prevalence of Burkitt lymphoma varies geographically, with higher rates observed in certain areas of Africa. It is believed that this geographical disparity is associated with factors such as the Epstein-Barr virus (EBV) infection and the prevalence of malaria in those regions.
Epidemiology of Burkitt Lymphoma
Burkitt lymphoma can be further classified into three subtypes:
- Endemic Burkitt lymphoma: Primarily affects children in equatorial Africa and is associated with the presence of the Epstein-Barr virus.
- Sporadic Burkitt lymphoma: Occurs in sporadic cases worldwide, with no geographical or age restrictions observed.
- Immunodeficiency-associated Burkitt lymphoma: Seen in individuals with compromised immune systems, such as those with HIV/AIDS.
To better understand Burkitt lymphoma and improve patient outcomes, extensive research is being conducted in the field of oncology and cancer research. This includes studying the genetic and molecular alterations underlying this disease, as well as identifying novel therapeutic targets.
| Key Characteristics of Burkitt Lymphoma | Prevalence | Classification |
|---|---|---|
| Fast-growing and aggressive nature | Varying rates worldwide, higher in certain African regions | Non-Hodgkin lymphoma subgroup |
| Can affect both children and adults | Associated with factors like EBV infection and malaria | Endemic, sporadic, immunodeficiency-associated |
The Role of Translocation in Cancer Genetics
In cancer genetics, gene translocation plays a crucial role in the development of various types of cancers. This process involves the rearrangement of genetic material between different chromosomes, leading to abnormal gene expression and the formation of cancerous cells.
Translocation can occur when segments of chromosomes break and reattach to different chromosomes, resulting in the fusion of genes that previously functioned separately. This fusion can give rise to novel proteins with altered functions, disrupting normal cellular processes and contributing to the initiation and progression of cancer.
One example of translocation’s significance is observed in leukemia, where the abnormal fusion of genes, such as BCR-ABL, leads to the uncontrolled growth of white blood cells. Similarly, translocation events involving oncogenes like MYC, BCL2, and BCL6 have been identified in different cancers, including Burkitt lymphoma, where they drive the oncogenic process.
The understanding of translocation mechanisms and their role in cancer pathogenesis has paved the way for targeted therapies that specifically address these genetic alterations. By targeting the abnormal fusion proteins or the signaling pathways they activate, oncologists and cancer researchers aim to disrupt the cancer cells’ growth and survival mechanisms, potentially leading to improved treatment outcomes.
Translocation and Targeted Therapy
Translocation events that result in the production of fusion proteins present attractive targets for therapeutic intervention. Identifying and inhibiting these abnormal proteins can disrupt the signaling pathways that drive cancer cell growth and promote tumor regression.
For example, in chronic myelogenous leukemia, the fusion protein BCR-ABL has been successfully targeted by small molecule inhibitors, such as imatinib, which specifically inhibit the activity of the abnormal protein. This targeted therapy has revolutionized the treatment of this disease, significantly improving patient outcomes.
Researchers continue to investigate the role of translocation in different types of cancers to identify novel therapeutic targets and develop more effective treatments. By understanding the underlying genetic alterations, oncologists can personalize treatment plans and improve patient outcomes in the field of oncology.
| Type of Cancer | Implicated Translocation | Targeted Therapy |
|---|---|---|
| Burkitt Lymphoma | MYC translocation | Anti-MYC targeted therapy |
| Follicular Lymphoma | BCL2 translocation | Anti-BCL2 targeted therapy |
| Diffuse Large B-Cell Lymphoma | BCL6 translocation | Anti-BCL6 targeted therapy |
MYC Translocation in Burkitt Lymphoma
Burkitt lymphoma is characterized by distinct genetic alterations, one of which is MYC translocation. MYC is an oncogene that plays a critical role in regulating cell growth and proliferation. In Burkitt lymphoma, the MYC gene undergoes rearrangement, resulting in its abnormal expression and contributing to the development and progression of the disease.
The c-MYC oncogene, located on chromosome 8, is involved in the control of cell cycle progression and plays a key role in cellular proliferation. In Burkitt lymphoma, the translocation involving MYC results in its relocation from its normal chromosomal position to another chromosome, typically chromosomes 2 or 22, where it is placed adjacent to immunoglobulin gene enhancers. This translocation leads to the dysregulation of MYC expression, driving uncontrolled cell growth and the formation of lymphoma cells.
Impact of MYC Translocation in Burkitt Lymphoma
The MYC translocation has significant implications in the pathogenesis of Burkitt lymphoma. The dysregulated MYC expression promotes the uncontrolled growth of B cells, resulting in the characteristic fast-growing nature of this lymphoma subtype. MYC translocation is considered a hallmark genetic event in Burkitt lymphoma and plays a crucial role in its diagnosis and prognosis.
MYC translocation in Burkitt lymphoma is commonly detected through molecular cytogenetic techniques, such as fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR). These methods allow for the identification of the specific chromosomal translocation involving MYC, confirming the diagnosis of Burkitt lymphoma and distinguishing it from other similar lymphomas.
| MYC Translocation | Frequency | Associated Prognosis |
|---|---|---|
| MYC translocation-positive | ~85-90% | Poor prognosis |
| MYC translocation-negative | ~10-15% | Better prognosis |
The presence of MYC translocation in Burkitt lymphoma is associated with a poor prognosis, indicating a more aggressive disease course. It often requires intensive treatment strategies to achieve favorable outcomes. However, advancements in targeted therapies and immunotherapies specifically designed to inhibit MYC signaling pathways have shown promise in improving treatment response and patient survival rates.
Understanding the role of MYC translocation in Burkitt lymphoma is crucial for the development of targeted therapies that can effectively disrupt the dysregulated MYC expression and halt the uncontrolled growth of lymphoma cells. Ongoing research in oncology and cancer research aims to further elucidate the molecular mechanisms underlying MYC translocation and explore novel therapeutic approaches for the management of Burkitt lymphoma.
Impact of BCL2 Translocation in Burkitt Lymphoma
In Burkitt lymphoma, BCL2 translocation plays a crucial role in the development and progression of the disease. The rearrangement of the BCL2 gene disrupts the normal process of apoptosis, which regulates cell death, leading to the survival of cancerous cells.
BCL2 is an anti-apoptotic gene that inhibits programmed cell death. With BCL2 translocation, the gene becomes dysregulated, resulting in the continuous suppression of apoptosis. As a consequence, cancerous cells evade cell death mechanisms, leading to uncontrolled cell proliferation and tumor growth.
This aberration in the BCL2 gene has significant implications in the diagnosis and treatment of Burkitt lymphoma. Detection of BCL2 translocation helps in confirming the presence of Burkitt lymphoma and distinguishing it from other lymphomas.
Table: Impact of BCL2 Translocation in Burkitt Lymphoma
| Impact of BCL2 Translocation | Implications |
|---|---|
| Suppression of apoptosis | Allows cancer cells to survive and proliferate uncontrollably |
| Specific marker for Burkitt lymphoma | Aids in accurate diagnosis and differentiation from other lymphomas |
| Potential therapeutic target | Enables the development of targeted therapies aimed at inhibiting BCL2 expression |
Understanding the impact of BCL2 translocation in Burkitt lymphoma is crucial for developing effective treatment strategies. Targeting the dysregulated BCL2 gene and restoring the balance of apoptosis may offer new therapeutic avenues for patients with Burkitt lymphoma.
BCL6 Translocation in Burkitt Lymphoma
Within the intricate landscape of Burkitt lymphoma, one key player emerges – BCL6 translocation. This genetic anomaly plays a crucial role in the development and progression of this aggressive form of lymphoma. When the BCL6 gene undergoes rearrangement, it disrupts the normal regulation of gene expression, leading to uncontrolled cell growth and ultimately contributing to the onset of Burkitt lymphoma.
The abnormal expression patterns resulting from BCL6 translocation alter the delicate balance within the lymphoid system, promoting the survival and growth of cancerous cells. This phenomenon highlights the significance of understanding the genetic underpinnings of Burkitt lymphoma and underscores the importance of research in the field of oncology and cancer research.
| Key Points |
|---|
| The BCL6 gene rearrangement is a critical event in Burkitt lymphoma. |
| BCL6 translocation disrupts the regulation of gene expression. |
| Uncontrolled cell growth contributes to the development of Burkitt lymphoma. |
| Understanding BCL6 translocation is vital for developing targeted therapies. |
Studying the mechanisms underlying BCL6 translocation sheds light on potential therapeutic targets for treating Burkitt lymphoma. By identifying novel ways to restore normal gene regulation in cancerous cells, researchers can develop targeted therapies that hold greater promise in battling this devastating disease.
Diagnosis of Burkitt Lymphoma through Translocation
Translocation plays a crucial role in the diagnosis of Burkitt lymphoma, aiding in the accurate identification of this specific type of lymphoma and guiding appropriate treatment decisions. By detecting specific translocations, such as MYC, BCL2, and BCL6, healthcare professionals can obtain valuable insights into the genetic alterations that drive the development and progression of Burkitt lymphoma.
Translocation analysis is typically performed through cytogenetic studies, such as karyotyping and fluorescence in situ hybridization (FISH), which allow for the visualization and identification of chromosomal abnormalities. These techniques enable oncologists to identify the characteristic translocations involving the MYC, BCL2, and BCL6 genes, which are hallmarks of Burkitt lymphoma.
Table: Translocations in Burkitt Lymphoma
| Translocation | Gene(s) Involved | Diagnostic Significance |
|---|---|---|
| MYC translocation | MYC gene | Highly specific to Burkitt lymphoma, aids in accurate diagnosis |
| BCL2 translocation | BCL2 gene | Identifies Burkitt lymphoma and distinguishes it from other lymphomas |
| BCL6 translocation | BCL6 gene | Supports the diagnosis of Burkitt lymphoma and helps determine treatment approach |
These specific translocations serve as valuable diagnostic markers for Burkitt lymphoma, allowing clinicians to differentiate it from other types of lymphomas. Additionally, identifying these translocations can provide insights into the aggressive nature of the disease and guide the selection of the most appropriate treatment strategies.
Through comprehensive analysis of translocations in Burkitt lymphoma, oncology specialists can ensure accurate diagnosis and tailor treatment plans based on the specific genetic alterations present in each patient. This precision approach enhances the prospects of achieving better outcomes and improved quality of life for individuals with Burkitt lymphoma.
Treatment Strategies for Burkitt Lymphoma
When it comes to managing Burkitt lymphoma, various treatment strategies are employed to address this aggressive form of lymphoma. These strategies take into account the genetic alterations that occur in the disease, aiming for targeted therapy and effective outcomes. The three main treatment modalities used for Burkitt lymphoma are:
- Targeted Therapy: This approach focuses on inhibiting specific molecular targets in cancer cells, exploiting the genetic alterations that drive the growth of Burkitt lymphoma. By precisely targeting these abnormalities, targeted therapy can effectively disrupt cancer cell signaling and inhibit tumor progression.
- Chemotherapy: Chemotherapy remains a cornerstone in the treatment of Burkitt lymphoma. It involves the administration of potent drugs that kill rapidly dividing cancer cells throughout the body. The intensive chemotherapy regimens used for Burkitt lymphoma have shown high response rates and the potential for cure, making it a vital component of treatment.
- Immunotherapy: Immunotherapy harnesses the power of the immune system to recognize and destroy cancer cells. In the case of Burkitt lymphoma, immunotherapeutic approaches aim to activate and enhance the body’s natural immune response against the cancer cells. This can be achieved through the use of immune checkpoint inhibitors, monoclonal antibodies, and other immune-enhancing agents.
Combination therapies that incorporate these treatment modalities have demonstrated improved outcomes and increased survival rates for patients with Burkitt lymphoma. The specific treatment plan will be tailored to individual patients, taking into consideration factors such as the extent of the disease, patient’s overall health, and response to initial therapy.
Treatment Comparison
In comparing the different treatment strategies for Burkitt lymphoma, it is essential to understand their respective benefits and limitations. Here is a table outlining the key characteristics and considerations for each treatment modality:
| Treatment Modality | Key Characteristics | Considerations |
|---|---|---|
| Targeted Therapy | – Selectively targets cancer cells with specific genetic alterations – Potentially less toxic to normal cells – Can lead to longer-lasting remissions |
– Limited to patients with identifiable genetic alterations – Resistance to targeted drugs can develop over time |
| Chemotherapy | – Broadly kills rapidly dividing cancer cells – High response rates – Potential for cure |
– Associated with more significant side effects – May require hospitalization for intensive treatment protocols |
| Immunotherapy | – Enhances the body’s natural immune response against cancer cells – Can provide durable responses – Potential for long-term immunological memory |
– Response rates may vary among different patients – Potential immune-related side effects |
By considering these factors and discussing the available options with a multidisciplinary team of oncology experts, the most appropriate treatment strategy can be selected for each patient diagnosed with Burkitt lymphoma. Ongoing research and advancements in the field of oncology and cancer research continue to explore new treatment possibilities that can further improve outcomes for individuals battling this disease.
Advances in Research and Future Directions
Continued research in the field of oncology and cancer research has led to significant advancements in understanding Burkitt lymphoma translocation and its implications for improved treatment outcomes. Scientists and medical professionals are working tirelessly to unravel the complexities of this genetic alteration, paving the way for novel therapeutic interventions.
Latest Discoveries in Cancer Research
Recent studies have shed light on the molecular mechanisms behind Burkitt lymphoma translocation, unraveling key insights into disease pathology and progression. Novel techniques, such as high-throughput sequencing and gene expression profiling, have helped identify additional genetic alterations that synergize with translocations, providing a more comprehensive understanding of this aggressive lymphoma.
The identification of specific translocation breakpoints has paved the way for targeted therapies that disrupt the oncogenic fusion transcripts responsible for driving cancer cell proliferation. Additionally, the development of advanced imaging techniques has greatly improved the ability to detect translocations non-invasively, enabling early diagnosis and timely intervention.
Future Directions in Therapeutic Interventions
Looking ahead, researchers are exploring exciting avenues to further enhance treatment outcomes for Burkitt lymphoma patients. These include:
- Developing personalized medicine approaches that leverage genomic profiling to identify patient-specific therapeutic targets
- Investigating the role of immune checkpoint inhibitors in boosting the immune response against Burkitt lymphoma
- Utilizing gene editing technologies, such as CRISPR-Cas9, to directly target translocation fusion genes and restore normal cellular function
- Exploring the potential of combination therapies that simultaneously target multiple oncogenic pathways
These research directions hold immense promise for the future of Burkitt lymphoma treatment, with the ultimate goal of improving patient outcomes and survival rates.
Collaborative Efforts and Collaborative Research
Advances in Burkitt lymphoma translocation research are made possible through both international collaboration and interdisciplinary teamwork. Researchers, clinicians, and pharmaceutical companies are actively collaborating to accelerate the development of targeted therapies and improve patient care.
Prominent institutions, such as the renowned Acibadem Healthcare Group, are at the forefront of these collaborative efforts, leveraging their expertise in oncology and cancer research to drive innovation and improve treatment outcomes. Their dedication to advancing cancer research is evidenced by their contribution to groundbreaking studies and clinical trials, shaping the future of Burkitt lymphoma treatment.
In conclusion, the ongoing advances in Burkitt lymphoma translocation research offer hope for improved therapies and better patient outcomes. By unraveling the complexities of this genetic alteration and exploring novel therapeutic interventions, researchers are striving to revolutionize the field of oncology and provide optimal care for individuals affected by this aggressive lymphoma.
Expertise of Acibadem Healthcare Group
When it comes to the treatment of Burkitt lymphoma and other types of cancer, the Acibadem Healthcare Group stands as a leading institution in the field of oncology. With their unwavering dedication to patient care and cutting-edge research, Acibadem Healthcare Group has continually pushed the boundaries of cancer treatment.
Their team of highly skilled oncologists and researchers is at the forefront of groundbreaking advancements in cancer research, striving to improve the understanding and management of various types of cancers, including Burkitt lymphoma. Through their extensive expertise and experience, Acibadem Healthcare Group provides patients with personalized and comprehensive treatment options that deliver the best possible outcomes.
Acibadem Healthcare Group’s commitment to oncology research is evident in their state-of-the-art facilities, equipped with the latest technologies and resources. This enables their team to conduct advanced diagnostic tests, perform intricate surgeries, and develop innovative therapies that target cancer at its core.
With a multidisciplinary approach to patient care, Acibadem Healthcare Group ensures that every aspect of a patient’s well-being is taken into consideration. From initial diagnosis to treatment, rehabilitation, and support, their compassionate and dedicated medical professionals provide comprehensive care and support to patients and their families.
Example Table: Acibadem Healthcare Group’s Excellence in Oncology
| Treatment Options | Research Contributions | Patient Care Services |
|---|---|---|
| Targeted Therapy | Development of novel cancer-targeting drugs | Patient education and counseling |
| Chemotherapy | Investigation into personalized chemotherapy regimens | Pain management and palliative care |
| Immunotherapy | Advancements in immunotherapeutic approaches | Psychosocial support for patients and families |
This table exemplifies Acibadem Healthcare Group’s excellence in oncology. Through their innovative treatment options, groundbreaking research contributions, and comprehensive patient care services, Acibadem Healthcare Group has established itself as a trusted institution for cancer treatment.
Conclusion
In conclusion, the study of Burkitt lymphoma translocation plays a critical role in the field of cancer genetics. The identification and understanding of specific gene rearrangements, such as MYC, BCL2, and BCL6 translocations, have helped in accurate diagnosis and targeted treatment strategies for Burkitt lymphoma. Through oncology research and advancements in cancer treatment, healthcare institutions like Acibadem Healthcare Group are at the forefront of improving patient care and outcomes.
The significance of Burkitt lymphoma translocation lies in its ability to disrupt normal gene expression and promote uncontrolled cell growth. By studying the genetic alterations associated with this disease, researchers have gained valuable insights into the mechanisms underlying lymphomagenesis and have developed more effective treatment approaches.
As ongoing research and future directions in cancer research continue to uncover new findings, there is hope for further advancements in the understanding and treatment of Burkitt lymphoma. The collaboration between oncologists, researchers, and institutions like Acibadem Healthcare Group plays a crucial role in driving progress and improving outcomes for patients with this aggressive form of lymphoma. Through continued dedication to cancer research and innovation, we can make significant strides in the fight against Burkitt lymphoma and other types of cancer.
FAQ
What is Burkitt lymphoma translocation?
Burkitt lymphoma translocation refers to a genetic rearrangement that occurs in the chromosomes of cells affected by Burkitt lymphoma. This translocation results in the abnormal positioning of genes, particularly the MYC gene, leading to the uncontrolled growth of cancerous cells.
What role does translocation play in cancer genetics?
Translocation plays a crucial role in cancer genetics by disrupting the normal functioning of genes. It can lead to the activation of oncogenes, like c-MYC in Burkitt lymphoma, and the inhibition of tumor suppressor genes, contributing to the development and progression of various types of cancers.
How does MYC translocation contribute to Burkitt lymphoma?
MYC translocation is a characteristic genetic alteration observed in Burkitt lymphoma. The rearrangement of the c-MYC oncogene results in its overexpression, leading to uncontrolled cell growth and the formation of tumors. This translocation is a key driver in the development of Burkitt lymphoma.
What is the impact of BCL2 translocation in Burkitt lymphoma?
BCL2 translocation in Burkitt lymphoma disrupts the normal regulation of apoptosis, a process that helps control cell death. The rearrangement of the BCL2 gene inhibits cell death, allowing the survival and proliferation of cancerous cells, contributing to the development of Burkitt lymphoma.
What role does BCL6 translocation play in Burkitt lymphoma?
BCL6 translocation in Burkitt lymphoma affects the expression and regulation of genes involved in cell growth and differentiation. The rearrangement of the BCL6 gene leads to uncontrolled cell growth and the formation of tumors, playing a critical role in the development of Burkitt lymphoma.
How can translocation help diagnose Burkitt lymphoma?
Translocation analysis, particularly for MYC, BCL2, and BCL6 genes, can aid in the accurate diagnosis of Burkitt lymphoma. Detecting these specific translocations through molecular techniques helps distinguish Burkitt lymphoma from other types of lymphoma and guides appropriate treatment strategies.
What treatment strategies are available for Burkitt lymphoma?
Treatment for Burkitt lymphoma typically involves a combination of targeted therapy, chemotherapy, and immunotherapy. Targeted therapy aims to specifically inhibit the activity of oncogenes like c-MYC. Chemotherapy and immunotherapy help eliminate cancer cells and boost the immune system's response to the disease.
What are the advancements in research and future directions for Burkitt lymphoma?
Ongoing research in Burkitt lymphoma focuses on understanding the underlying molecular mechanisms of translocation and identifying new therapeutic targets. Advances in cancer research, such as precision medicine and immunotherapies, hold promise for improved treatment outcomes in the future.
What is the expertise of Acibadem Healthcare Group in treating Burkitt lymphoma?
Acibadem Healthcare Group is a renowned institution known for its expertise in oncology and cancer research. They have a multidisciplinary team of specialists dedicated to providing comprehensive care to patients with Burkitt lymphoma and other types of cancer, ensuring the best possible treatment outcomes.
Why is understanding Burkitt lymphoma translocation important in oncology and cancer research?
Understanding Burkitt lymphoma translocation is crucial in oncology and cancer research as it provides valuable insights into the genetic mechanisms of cancer development. It helps in accurate diagnosis, personalized treatment strategies, and the development of targeted therapies for Burkitt lymphoma and other related cancers.
ACIBADEM Healthcare Group Hospitals and Clinics
With a network of hospitals and clinics across 5 countries, including 40 hospitals, ACIBADEM Healthcare Group has a global presence that allows us to provide comprehensive healthcare services to patients from around the world. With over 25,000 dedicated employees, we have the expertise and resources to deliver unparalleled healthcare experiences. Our mission is to ensure that each patient receives the best possible care, supported by our commitment to healthcare excellence and international healthcare standards. Ready to take the first step towards a healthier future? Contact us now to schedule your Free Consultation Health session. Our friendly team is eager to assist you and provide the guidance you need to make informed decisions about your well-being. Click To Call Now !*The information on our website is not intended to direct people to diagnosis and treatment. Do not carry out all your diagnosis and treatment procedures without consulting your doctor. The contents do not contain information about the therapeutic health services of ACIBADEM Health Group.